

# CITATION REPORT

List of articles citing

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

DOI: 10.1093/eurheartj/ehu505

European Heart Journal, 2015, 36, 1163-70.

**Source:** <https://exaly.com/paper-pdf/61714921/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
530	Use of relative survival to evaluate non-ST-elevation myocardial infarction quality of care and clinical outcomes. <b>2015</b> , 1, 85-91		12
529	The role of national registries. <i>European Heart Journal</i> , <b>2015</b> , 36, 1155-6	9.5	0
528	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <b>2015</b> , 65, 2211-21		193
527	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , <b>2016</b> , 37, 390-9	9.5	232
526	Dual antiplatelet therapy use by Canadian cardiac surgeons. <b>2015</b> , 150, 1548-54.e3		16
525	Antiplatelet therapy in acute coronary syndromes. <b>2015</b> , 16, 2133-47		19
524	Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. <b>2015</b> , 66, 1273-1285		79
523	Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding. <b>2015</b> , 20, 132		1
522	"One-Time" versus Staged Multivessel Intervention in Intermediate to Very High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. <b>2016</b> , 46, 774-783		3
521	GHSR-1a is a novel pro-angiogenic and anti-remodeling target in rats after myocardial infarction. <b>2016</b> , 788, 218-225		18
520	A critical review on the translational journey of cardioprotective therapies!. <b>2016</b> , 220, 176-84		25
519	Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. <b>2016</b> , 6, e010880		27
518	Regional Clinical Alliance Path and Cardiac Rehabilitation After Hospital Discharge for Acute Myocardial Infarction Patients in Japan - A Nationwide Survey. <b>2016</b> , 80, 1750-5		13
517	Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome. <b>2016</b> , 16, 226		13
516	Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease. <b>2016</b> , 6, 24619		21
515	Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. <b>2016</b> , 6, e012604		18
514	Prevalencia y pronóstico de los pacientes con infarto de miocardio de alto riesgo candidatos a doble tratamiento antiagregante prolongado. <b>2016</b> , 69, 480-487		9

513	Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy. <b>2016</b> , 69, 480-7	0
512	Prognostic significance of whole blood viscosity estimated by de Simone's formula in ST-elevation myocardial infarction. <b>2016</b> , 10, 495-511	13
511	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <b>2016</b> , 32, S15-34	7
510	Frailty is a short-term prognostic marker in acute coronary syndrome of elderly patients. <b>2016</b> , 5, 434-40	41
509	In an era of rapid STEMI reperfusion with Primary Percutaneous Coronary Intervention is there a role for adjunct therapeutic hypothermia? A structured literature review. <b>2016</b> , 223, 883-890	3
508	Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. <b>2016</b> , 34, 450-459	15
507	Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?. <b>2016</b> , 68, 1223-1232	6
506	Challenges in secondary prevention after acute myocardial infarction: A call for action. <b>2016</b> , 23, 1994-2006	88
505	Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de Cardiología. <b>2016</b> , 69, 1083-1087	24
504	[Lipid-lowering therapy in Europe and the United States - treat to target or fire and forget?]. <b>2016</b> , 141, 857-62	1
503	Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. <b>2016</b> , 12, 1491-1502	2
502	Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. <b>2016</b> , 69, 1083-1087	1
501	Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. <b>2016</b> , 219, 387-93	12
500	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <b>2016</b> , 80, 791-801	13
499	[Hypercholesterolemia - Where are we today? Where are we going?]. <b>2016</b> , 41, 413-20	1
498	Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing. <i>European Heart Journal</i> , <b>2016</b> , 37, 2085-7	9.5
497	Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations. <b>2016</b> , 353, i3163	12
496	Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. <b>2016</b> , 16, 115	34

495	Which long-term antiplatelet regimen for patients with acute coronary syndromes?. <b>2016</b> , 30, 333-8		
494	Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study. <b>2016</b> , 2, 291-298		12
493	Dual antiplatelet therapy after coronary stenting. <b>2016</b> , 17, 1775-87		9
492	Novel risk factors for acute coronary syndromes and emerging therapies. <b>2016</b> , 220, 815-24		7
491	Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction. <b>2016</b> , 128, 450-7		2
490	[Hypoglycemia--simply annoying or dangerous?]. <b>2016</b> , 158, 67-70		
489	Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. <b>2016</b> , 12, 405-18		7
488	The year in cardiology 2015: acute coronary syndromes. <i>European Heart Journal</i> , <b>2016</b> , 37, 221-8	9.5	10
487	Validation of a New Risk Score for Predicting Post-discharge Cardiovascular Events in Patients With Acute Coronary Syndrome. <b>2016</b> , 69, 338-40		
486	Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. <b>2016</b> , 50, 99-107		30
485	Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials. <b>2016</b> , 176, 36-43		7
484	Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. <b>2016</b> , 2, 172-183		60
483	Validaci3n de una nueva escala de riesgo para predecir eventos cardiovasculares poshospitalizaci3n en pacientes con s3ndrome coronario agudo. <b>2016</b> , 69, 338-340		1
482	Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. <b>2016</b> , 102, 783-9		18
481	Atherosclerosis: Successes, Surprises, and Future Challenges. <b>2016</b> , 118, 531-4		168
480	The Risk of Cardiovascular Events After an Acute Coronary Event Remains High, Especially During the First Year, Despite Revascularization. <b>2016</b> , 69, 11-8		11
479	El riesgo de eventos cardiovasculares tras un evento coronario agudo persiste elevado a pesar de la revascularizaci3n, especialmente durante el primer a3o. <b>2016</b> , 69, 11-18		66
478	Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus. <b>2016</b> , 117, 1088-94		13

477	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <b>2016</b> , 26, 321-34		3
476	Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry. <b>2016</b> , 23, 340-8		43
475	Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?. <i>European Heart Journal</i> , <b>2016</b> , 37, 868-72	9.5	49
474	Long-term clinical outcomes, health-related quality of life, and costs in different treatment modalities of stable coronary artery disease. <b>2017</b> , 3, 74-82		5
473	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <b>2017</b> , 20, 555-564		39
472	Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all. <i>European Heart Journal</i> , <b>2017</b> , 38, 801-803	9.5	25
471	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <b>2017</b> , 236, 54-60		19
470	Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. <b>2017</b> , 17, 53		106
469	Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. <b>2017</b> , 12, 38-43		17
468	Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion. <b>2017</b> , 121, 31-42		94
467	Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. <b>2017</b> , 66, 507-514.e1		43
466	[Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept]. <b>2017</b> , 159, 49-52		
465	The second myocardial infarction: Higher risk factor burden and earlier second myocardial infarction in women compared with men. The Northern Sweden MONICA study. <b>2017</b> , 16, 418-424		4
464	Challenges in secondary prevention after acute myocardial infarction: A call for action. <b>2017</b> , 6, 299-310		16
463	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. <b>2017</b> , 240, 30-36		11
462	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. <b>2017</b> , 24, 88-100		36
461	Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction. <b>2017</b> , 6, 273-280		5
460	Who needs secondary prevention?. <b>2017</b> , 24, 8-13		5

459	Challenges in secondary prevention after acute myocardial infarction: A call for action. <b>2017</b> , 16, 369-380	9
458	Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up. <b>2017</b> , 90, 31-37	12
457	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , <b>2017</b> , 38, 1048-1055	9.5 33
456	Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. <b>2017</b> , 83, 2056-2065	20
455	Echoluency of the carotid artery is associated with short-term plaque progression and positive remodeling in the culprit coronary artery in AMI survivors. <b>2017</b> , 70, 438-445	5
454	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. <b>2017</b> , 14, 77-87	16
453	Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study. <b>2017</b> , 35, e12237	2
452	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. <b>2017</b> , 6, 119-129	2
451	Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry). <b>2017</b> , 119, 692-697	2
450	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <b>2017</b> , 4, e000651	28
449	Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology. <b>2017</b> , 18, 1-9	3
448	Stable High-Sensitivity Cardiac Troponin T Levels and Outcomes in Patients With Chest Pain. <b>2017</b> , 70, 2226-2236	69
447	Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. <b>2017</b> , 70, 2278-2289	293
446	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <b>2017</b> , 2, 1069-1078	91
445	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. <b>2017</b> , 245, 35-42	3
444	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <b>2017</b> , 70, 1368-1375	50
443	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. <b>2017</b> , 70, 527-538	17
442	Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes. <b>2017</b> , 245, 1-5	13

441	Gut Microbiota: A New Marker of Cardiovascular Disease. <b>2017</b> , 23, 3233-3238	20
440	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <b>2017</b> , 6,	21
439	Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway. <b>2017</b> , 3, 132-133	4
438	Mechanisms of erosion of atherosclerotic plaques. <b>2017</b> , 28, 434-441	80
437	Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study. <b>2017</b> , 17, 75	14
436	Personality factors and depression as predictors of hospital-based health care utilization following acute myocardial infarction. <b>2017</b> , 16, 318-325	3
435	Rationale and design of the long-Term risk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. <b>2017</b> , 40, 1197-1204	7
434	Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry. <b>2017</b> , 6,	74
433	One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper. <b>2017</b> , 72, 19-27	2
432	Prognostic Value of New-Generation Troponins in ST-Segment-Elevation Myocardial Infarction in the Modern Era: The RUTI-STEMI Study. <b>2017</b> , 6,	12
431	PEGASUS study: who would benefit from prolonged DUAL antiplatelet therapy?. <b>2017</b> , 18 Suppl 1, e100-e104	0
430	Coronary Artery Disease in Premenopausal and Postmenopausal Women. <b>2017</b> , 58, 174-179	9
429	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. <b>2017</b> , 122, 224-233	12
428	Leukocyte Trafficking in Cardiovascular Disease: Insights from Experimental Models. <b>2017</b> , 2017, 9746169	29
427	Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline. <b>2017</b> , 17, 224	4
426	PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW. <b>2017</b> , 13, 558-564	1
425	Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database. <b>2017</b> , 23, 684-690	
424	Thyroid Hormones and Cardiovascular Function and Diseases. <b>2018</b> , 71, 1781-1796	148

423	Effectiveness of discharge education on outcomes in acute coronary syndrome patients: a systematic review protocol. <b>2018</b> , 16, 817-824		1
422	Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients. <b>2018</b> , 71, 829-836		4
421	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. <b>2018</b> , 138, 756-766		136
420	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , <b>2018</b> , 39, 1078-1085	9.5	73
419	Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). <b>2018</b> , 7, e007174		17
418	Mediterranean diet improves endothelial function in patients with diabetes and prediabetes: A report from the CORDIOPREV study. <b>2018</b> , 269, 50-56		32
417	Duration of Dual Antiplatelet Therapy in the Post-Acute Coronary Syndrome Patient. <b>2018</b> , 33, 248-254		
416	Economic and social impact of increased cardiac rehabilitation uptake and cardiac telerehabilitation in Belgium - a cost-benefit analysis. <b>2018</b> , 73, 222-229		15
415	Effects of combined high-intensity aerobic interval training program and Mediterranean diet recommendations after myocardial infarction (INTERFARCT Project): study protocol for a randomized controlled trial. <b>2018</b> , 19, 156		7
414	Optimal duration of dual antiplatelet therapy for coronary artery disease. <b>2018</b> , 26, 321-333		6
413	Predictors of health-related quality of life in korean patients with myocardial infarction: a longitudinal observational study. <b>2018</b> , 47, 142-148		5
412	P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use. <b>2018</b> , 19 Suppl 1, e9-e12		1
411	Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. <b>2018</b> , 20, B21-B28		1
410	Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. <b>2018</b> , 4, 25-35		20
409	[Secondary prevention with antiplatelet therapy in cardiac rehabilitation]. <b>2018</b> , 168, 16-22		
408	First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005-2015. <b>2018</b> , 104, 51-57		15
407	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. <b>2018</b> , 250, 49-55		4
406	Subacute and Chronic Left Ventricular Myocardial Scar: Accuracy of Texture Analysis on Nonenhanced Cine MR Images. <b>2018</b> , 286, 103-112		99



405	Preventing recurrent events in survivors of acute coronary syndromes in Australia: consensus recommendations using the Delphi process. <b>2018</b> , 34, 551-558	
404	What is the role of beta-blockers in a contemporary treatment cohort of patients with acute coronary syndrome? A propensity-score matching analysis. <b>2018</b> , 37, 901-908	5
403	Gesundheitsökonomische Aspekte der Verschreibung von PCSK9-Hemmern. <b>2018</b> , 18, 34-37	
402	All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study. <b>2018</b> , 14, 383-392	1
401	Dual antiplatelet therapy in acute coronary syndrome after stent implantation: How short is short and how long is long?. <b>2018</b> , 59, 376-377	1
400	Effect of Previous Cardiovascular Diseases on Long-Term Outcomes of Acute Myocardial Infarction: Data of the Outpatient Registry "PROFILE-IM". <b>2018</b> , 14, 741-746	2
399	What is the role of beta-blockers in a contemporary treatment cohort of patients with acute coronary syndrome? A propensity-score matching analysis. <b>2018</b> , 37, 901-908	8
398	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <b>2018</b> , 379, 2097-2107	1277
397	Impacto pronóstico diferencial del infarto de miocardio comparado con la gravedad de la hemorragia sobre la mortalidad en pacientes contemporáneos con síndrome coronario agudo. <b>2018</b> , 71, 829-836	9
396	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. <b>2018</b> , 72, 2886-2903	33
395	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <b>2018</b> , 277, 334-340	18
394	Anticoagulant Therapy for Acute Coronary Syndromes. <b>2018</b> , 13, 87-92	6
393	Relation of Chronic Myocardial Injury and Non-ST-Segment Elevation Myocardial Infarction to Mortality. <b>2018</b> , 122, 1989-1995	8
392	Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?. <b>2018</b> , 32, 2095-2104	5
391	Patient empowerment and general self-efficacy in patients with coronary heart disease: a cross-sectional study. <b>2018</b> , 19, 76	24
390	Clinical implications of high-sensitivity cardiac troponins. <b>2018</b> , 284, 50-60	8
389	Fluorescence immunosensor for cardiac troponin T based on Förster resonance energy transfer (FRET) between carbon dot and MoS nano-couple. <b>2018</b> , 20, 16501-16509	27
388	Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <b>2018</b> , 7,	7

387	Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study. <b>2018</b> , 4, 10-17	12
386	Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization. <b>2018</b> , 4, 195-201	3
385	Mécanismes d'érosion superficielle des plaques d'athérosclérose. <b>2018</b> , 2018, 22-26	
384	Drug Adherence in Hypertension and Cardiovascular Protection. <b>2018</b> ,	2
383	Naked physically synthesized gold nanoparticles affect migration, mitochondrial activity, and proliferation of vascular smooth muscle cells. <b>2018</b> , 13, 3163-3176	10
382	Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review. <b>2018</b> , 130, 694-697	
381	Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. <b>2018</b> , 114, 1445-1461	45
380	Long Non-Coding RNAs in Vascular Inflammation. <b>2018</b> , 5, 22	15
379	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. <b>2018</b> , 15, 387-395	3
378	Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept?. <b>2018</b> , 138, 150-153	15
377	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. <b>2018</b> , 7,	16
376	Prognostic value of pulse pressure after an acute coronary syndrome. <b>2018</b> , 277, 219-226	11
375	Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care: a retrospective observational study. <b>2018</b> , 18, 167	3
374	Remote Endothelial Activation Following Myocardial Infarction: A New Target to Combat Recurrent Cardiovascular Events?. <b>2018</b> , 72, 1027-1029	
373	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. <b>2018</b> , 273, 8-14	13
372	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <b>2018</b> , 20, F1-F74	17
371	Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence. <i>European Heart Journal</i> , <b>2018</b> , 39, 2365-2367	9.5 5
370	Long-term dual antiplatelet therapy: pharmacological and clinical implications. <b>2018</b> , 19, 399-410	

369	Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction. <b>2018</b> , 123, 579-589		41
368	From Prevention to Rehabilitation: Toward a Comprehensive Approach to Tackling Cardiac Arrest. <b>2019</b> , 72, 3-6		
367	Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. <i>European Heart Journal</i> , <b>2019</b> , 40, 1466-1471	9.5	17
366	Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. <b>2019</b> , 26, 215-218		2
365	Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI. <b>2019</b> , 9, 11647		18
364	Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial. <b>2019</b> , 83, 2025-2033		14
363	The Evolution of βBlockers in Coronary Artery Disease and Heart Failure (Part 1/5). <b>2019</b> , 74, 672-682		16
362	Oxidative Stress Reduction (Prong-3). <b>2019</b> , 139-254		
361	Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes. <b>2019</b> , 74, 774-782		2
360	Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives. <b>2019</b> , 89,		1
359	Inflammation as a Therapeutic Target in Atherosclerosis. <b>2019</b> , 8,		79
358	Long-Term Risk Factor Control After Myocardial Infarction-A Need for Better Prevention Programmes. <b>2019</b> , 8,		4
357	Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention. <b>2019</b> , 8, e012433		3
356	High-Intensity Interval Training in Cardiac Rehabilitation: Impact on Fat Mass in Patients With Myocardial Infarction. <b>2019</b> , 94, 1718-1730		19
355	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study. <b>2019</b> , 42, 1113-1120		4
354	Determinants of suboptimal long-term secondary prevention of acute myocardial infarction: the structural interview method and physical examinations. <b>2019</b> , 19, 243		2
353	Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events. <b>2019</b> , 74, 2047-2055		8
352	Climate-related Risk and Financial Statements: Implications for Regulators, Preparers, Auditors and Users. <b>2019</b> , 29, 599-605		3

351	Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database. <b>2019</b> , 8, 329-343	1
350	Impact of new-onset diabetes on clinical outcomes after ST segment-elevated myocardial infarction. <b>2019</b> , 53, 379-384	0
349	Effects of "plate model" as a part of dietary intervention for rehabilitation following myocardial infarction: a randomized controlled trial. <b>2019</b> , 9, 179-188	4
348	PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. <b>2019</b> , 13, 714-720	5
347	Secondary cardiovascular prevention in clinical practice: what do we need today?. <b>2019</b> , 89,	1
346	Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. <b>2019</b> , 42, 391-399	21
345	Modifiable Risk Factors in Young Adults With First Myocardial Infarction. <b>2019</b> , 73, 573-584	52
344	Key inflammatory mechanisms underlying heart failure. <b>2019</b> , 44, 96-106	40
343	Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland. <b>2019</b> , 19, 123	12
342	Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. <b>2019</b> , 120, 106566	9
341	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <b>2019</b> , 5, 200-206	17
340	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <b>2019</b> , 18, 71	64
339	ST-segment elevation myocardial infarction. <b>2019</b> , 5, 39	78
338	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. <b>2019</b> , 11, S28-S39	
337	Un risque thrombotique persistant malgré les traitements de référence. <b>2019</b> , 11, S4-S10	
336	What is the best way of organizing the follow-up of patients with cardiovascular disease?. <b>2019</b> , 26, 1968-1970	1
335	Impact of Multiple Myocardial Scars Detected by CMR in Patients Following STEMI. <b>2019</b> , 12, 2168-2178	6
334	Spermidine-enhanced autophagic flux improves cardiac dysfunction following myocardial infarction by targeting the AMPK/mTOR signalling pathway. <b>2019</b> , 176, 3126-3142	29

333	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <b>2019</b> , 285, 135-146	106
332	The role of serial carotid intima-media thickness assessment as a surrogate marker of atherosclerosis control in patients with recent myocardial infarction. <b>2019</b> , 15, 74-80	3
331	Statin-associated muscle symptoms in coronary patients: design of a randomized study. <b>2019</b> , 53, 162-168	4
330	Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study. <b>2019</b> , 9, e027199	2
329	Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease. <b>2019</b> , 8, 2048004019841971	2
328	Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. <b>2019</b> , 119, 1583-1589	5
327	Inflammation in coronary artery disease: Which biomarker and which treatment?. <b>2019</b> , 26, 869-871	8
326	Most Promising Therapies in Interventional Cardiology. <b>2019</b> , 21, 26	3
325	The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial. <b>2019</b> , 14, 922-934	2
324	Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease. <b>2019</b> , 19, 71	10
323	One-Year Outcomes of Patients With Established Coronary Artery Disease Presenting With Acute Coronary Syndromes. <b>2019</b> , 123, 1387-1392	6
322	Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. <b>2019</b> , 2019, 8295054	63
321	New evidence on the role of inflammation in CVD risk. <b>2019</b> , 34, 418-423	16
320	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <b>2019</b> , 37, 316-337	5
319	Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study. <b>2019</b> , 19, 253	8
318	High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study. <b>2019</b> , 89,	4
317	Unplanned Readmissions After Acute Myocardial Infarction: 1-Year Trajectory Following Discharge From a Safety Net Hospital. <b>2019</b> , 18, 72-74	1
316	Prolonged DAPT following a myocardial infarction: Is there a role for the DAPT score?. <b>2019</b> , 60, 303-304	

315	Is proteomics of value in cardiovascular risk assessment?. <b>2019</b> , 30, 452-461	2
314	Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity. <b>2019</b> , 59, 427-436	6
313	The relationship between phobic anxiety and 2-year readmission after Acute Coronary Syndrome: What is the role of heart rate variability?. <b>2019</b> , 247, 73-80	5
312	Clinical Features and Prognosis of Patients with Acute and Chronic Myocardial Injury Admitted to the Emergency Department. <b>2019</b> , 132, 614-621	8
311	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <b>2019</b> , 278, 7-13	11
310	De la prevenci3n a la rehabilitaci3n: hacia un manejo integral de la parada cardiaca. <b>2019</b> , 72, 3-6	3
309	Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. <b>2019</b> , 42, 111-119	26
308	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <b>2019</b> , 208, 81-90	16
307	Intrinsic Vascular Repair by Endothelial Progenitor Cells in Acute Coronary Syndromes: an Update Overview. <b>2019</b> , 15, 35-47	13
306	A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction. <b>2019</b> , 278, 1-6	8
305	Can cardiac rehabilitation improve LDL-cholesterol target attainment after acute coronary syndromes?. <b>2019</b> , 26, 246-248	1
304	Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function. <b>2019</b> , 8, 628-636	8
303	Predictors of subsequent myocardial infarction, stroke, and death in stable post-myocardial infarction patients: A nationwide cohort study. <b>2019</b> , 8, 634-642	11
302	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. <b>2020</b> , 9, 788-801	1
301	Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. <b>2020</b> , 27, 696-705	17
300	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <b>2020</b> , 9, 589-598	6
299	[Comparison of the prognostic value of different clinical, angiographic and scintigraphic scores in stable coronary patients after acute coronary syndrome]. <b>2020</b> , 69, 12-23	
298	Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction. <b>2020</b> , 75, 66-73	7

297	The myth of 'stable' coronary artery disease. <b>2020</b> , 17, 9-21	39
296	Improving the Monitoring of Cardiac Rehabilitation Delivery and Quality: A Call to Action for Australia. <b>2020</b> , 29, 1-4	1
295	Patients' Experiences of Cardiovascular Health Education and Risk Communication: A Qualitative Synthesis. <b>2020</b> , 30, 88-104	11
294	Health-related quality of life and exercise-based cardiac rehabilitation in contemporary acute coronary syndrome patients: a systematic review and meta-analysis. <b>2020</b> , 29, 579-592	13
293	Plasma and Dietary Linoleic Acid and 3-Year Risk of Type 2 Diabetes After Myocardial Infarction: A Prospective Analysis in the Alpha Omega Cohort. <b>2020</b> , 43, 358-365	6
292	Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. <b>2020</b> , 7, 264-273	8
291	Defining and managing patients with non-ST-elevation myocardial infarction: Sorting through type 1 vs other types. <b>2020</b> , 43, 242-250	4
290	Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses. <b>2020</b> , 20, 239-248	6
289	Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. <b>2020</b> , 120, 75-82	8
288	Clinical usefulness of instantaneous wave-free ratio for the evaluation of coronary artery lesion with prior myocardial infarction: A multi-center study. <b>2020</b> , 26, 100431	1
287	Application of a mechanically responsive, inflammatory macrophage-targeted dual-sensitive hydrogel drug carrier for atherosclerosis. <b>2020</b> , 186, 110718	15
286	Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy. <b>2020</b> , 57, 513-526	11
285	Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland. <b>2020</b> , 76, 257-265	3
284	CHADS-VASc Score and In-Hospital Mortality in Critically Ill Patients With New-Onset Atrial Fibrillation. <b>2020</b> , 34, 1165-1171	2
283	Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. <b>2020</b> , 42, 2084-2097	3
282	Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <b>2021</b> , 37, 776-785	27
281	Mortality and healthcare resource utilization following acute myocardial infarction according to adherence to recommended medical therapy guidelines. <b>2020</b> , 124, 1200-1208	2
280	Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization. <b>2020</b> , 59, 61-74	1

279	In-hospital cardiac rehabilitation and clinical outcomes in patients with acute myocardial infarction after percutaneous coronary intervention: a retrospective cohort study. <b>2020</b> , 10, e039096		3
278	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice. <b>2020</b> , 9,		2
277	Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C monocytosis in apolipoprotein E knockout mice. <b>2020</b> , 48, 300060520932816		1
276	Mortality and Major Cardiovascular Events in Ischemic Heart Disease Are Associated with Nonthyroidal Illness and Thyroid Hormone Deficiency. <b>2020</b> , 32, 324-326		
275	Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study. <i>European Heart Journal</i> , <b>2021</b> , 42, 2577-2586	9.5	6
274	Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease. <b>2020</b> , 10, 21345		0
273	Neutrophils as a Novel Target of Modified Low-Density Lipoproteins and an Accelerator of Cardiovascular Diseases. <b>2020</b> , 21,		9
272	Elevated FURIN levels in predicting mortality and cardiovascular events in patients with acute myocardial infarction. <b>2020</b> , 111, 154323		6
271	Circulating Omega-3 Fatty Acids and Incident Adverse Events in Patients With Acute Myocardial Infarction. <b>2020</b> , 76, 2089-2097		14
270	How and why a multifaceted intervention to improve adherence post-MI worked for some (and could work better for others): an outcome-driven qualitative process evaluation. <b>2020</b> , 10, e036750		3
269	Evidence-practice gaps in P2Y inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia. <b>2020</b> ,		1
268	Correlation between serum free triiodothyronine levels and risk stratification in Chinese patients with acute coronary syndrome receiving percutaneous coronary intervention. <b>2020</b> , 48, 300060520957180		1
267	The effect of problem-based learning after coronary heart disease - a randomised study in primary health care (COR-PRIM). <b>2020</b> , 20, 370		2
266	Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. <b>2020</b> , 142, 1890-1900		96
265	Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome. <b>2020</b> , 21, 1317-1327		2
264	Clinical characteristics and outcomes of young adults with first myocardial infarction: Results from Gulf COAST. <b>2020</b> , 31, 100680		1
263	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. <b>2021</b> , 121, 1161-1168		1
262	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. <b>2020</b> , 10, 22121		2



261	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <b>2020</b> , 9, e018897	9
260	Nicht pharmakologische Sekundärprävention und Rehabilitation: aktuelle Evidenz. <b>2020</b> , 9, 297-302	
259	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <b>2020</b> , 76, 2436-2446	23
258	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <b>2020</b> , 1	6
257	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <b>2020</b> , 7, 582826	2
256	Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease. <b>2020</b> , 22, 1070-1079	4
255	Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome. <b>2020</b> , 106, 506-511	4
254	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <b>2021</b> , 7, 486-495	18
253	Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. <b>2021</b> , 32, 533-541	3
252	Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships. <b>2020</b> , 10, 4315	4
251	Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus [Polish multicenter study POLASPIRE]. <b>2020</b> ,	2
250	Translation and validation of the cardiac rehabilitation barriers scale in the Czech Republic (CRBS-CZE): Protocol to determine the key barriers in East-Central Europe. <b>2020</b> , 99, e19546	5
249	The importance of considering both primary and secondary diagnostic codes when using administrative health data to study acute coronary syndrome epidemiology (ANZACS-QI 47). <b>2021</b> , 7, 548-555	3
248	Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. <b>2020</b> , 19, 108	22
247	Secondary cardiovascular prevention in patients with previous myocardial infarction: an individualized approach difficult to be tailored. <b>2020</b> , 21, 610-612	
246	Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass. <b>2020</b> , 110, 13-19	2
245	Genetic predisposition to coronary artery disease is predictive of recurrent events: a Chinese prospective cohort study. <b>2020</b> , 29, 1044-1053	6
244	Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. <b>2020</b> , 50, 421-429	0

243	Analysis of situation of acute coronary syndrome based on the date of the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project: single-centre observational study. <b>2020</b> , 96, 742-746		0
242	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. <b>2020</b> , 2020, 3856242		5
241	Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population. <b>2020</b> , 20, 61		4
240	Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. <b>2021</b> , 1307, 153-169		8
239	To be seen as a unique person after suffering a second myocardial infarction: Expressed needs of patients and descriptions of personnel. <b>2020</b> , 57, 102797		1
238	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: further evidence fuelling the dual target concept. <i>European Heart Journal</i> , <b>2020</b> , 41, 2962-2964	9.5	4
237	A perspective on targeting inflammation and cytokine actions in atherosclerosis. <b>2020</b> , 12, 613-626		11
236	Hematopoiesis and Cardiovascular Disease. <b>2020</b> , 126, 1061-1085		37
235	Follow-up strategies and individual risk profile after percutaneous coronary intervention: The prospective post percutaneous coronary intervention registry. <b>2021</b> , 97, E209-E218		
234	Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?. <b>2021</b> , 35, 627-635		7
233	Antithrombotic therapy for patients with chronic coronary syndromes. <b>2021</b> , 107, 925-933		6
232	Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study. <b>2021</b> , 109, 443-451		4
231	Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation. <b>2021</b> , 14, 3-12		8
230	Systematic review and meta-analysis of the clinical characteristics and outcomes of spontaneous coronary artery dissection. <b>2021</b> , 322, 34-39		4
229	Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. <b>2021</b> , 143, 528-539		73
228	Immature Platelets and Risk of Cardiovascular Events among Patients with Ischemic Heart Disease: A Systematic Review. <b>2021</b> , 121, 659-675		4
227	Challenges in coronary heart disease prevention - experiences from a long-term follow-up study in Norway. <b>2021</b> , 55, 73-81		0
226	Differential Vascular Responses to New-Generation Drug-Eluting Stenting According to Clinical Presentation: Three-Month Optical Coherence Tomographic Study. <b>2021</b> , 72, 381-391		

225	Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms. <i>European Heart Journal</i> , <b>2021</b> , 42, 938-947	9.5	13
224	Endophilin A2-mediated alleviation of endoplasmic reticulum stress-induced cardiac injury involves the suppression of ERO1 $\alpha$ /IPR signaling pathway. <b>2021</b> , 17, 3672-3688		0
223	Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. <b>2020</b> , 11, 582929		5
222	Stepwise regression of non-culprit lipid-rich plaque observed using serial near-infrared spectroscopy-intravascular ultrasound and optical coherence tomographic measurements after aggressive cholesterol-lowering treatment: a case report. <b>2021</b> , 5, ytab095		
221	In-hospital and 30-day major adverse cardiac events in patients referred for ST-segment elevation myocardial infarction in Dhaka, Bangladesh. <b>2021</b> , 21, 85		1
220	Social inequalities in mild and severe myocardial infarction: how large is the gap in health expectancies?. <b>2021</b> , 21, 259		3
219	How inflammation heats the heart. <i>European Heart Journal</i> , <b>2021</b> , 42, 875-878	9.5	1
218	High Job Burnout Predicts Low Heart Rate Variability in the Working Population after a First Episode of Acute Coronary Syndrome. <b>2021</b> , 18,		1
217	ECG changes after non-cardiac surgery: a prospective observational study in intermediate-high risk patients. <b>2021</b> , 87, 283-293		1
216	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.. <b>2022</b> , 28, 1795-1806		0
215	Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome. <b>2021</b> ,		2
214	Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study. <b>2021</b> , 36, 1506-1513		0
213	Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial. <b>2021</b> , 323, 37-43		3
212	Lipid-lowering therapy and percutaneous coronary interventions. <b>2021</b> , 16, 1389-1403		2
211	Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art. <b>2021</b> , 10,		2
210	Modern NCDR and ACTION risk models outperform the GRACE model for prediction of in-hospital mortality in acute coronary syndrome in a German cohort. <b>2021</b> , 329, 28-35		1
209	Citric Acid Cycle Metabolites Predict Infarct Size in Submitted to Transient Coronary Artery Occlusion and Treated with Succinate Dehydrogenase Inhibitors or Remote Ischemic Perconditioning. <b>2021</b> , 22,		2
208	Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis. <b>2021</b> , 100, e26070		0

207	Multimodality Intravascular Imaging of High-Risk Coronary Plaque. <b>2021</b> , 15, 145-145	8
206	Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.	
205	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. <b>2021</b> , 16, e26	2
204	Assessment of stunned and viable myocardium using manganese-enhanced MRI. <b>2021</b> , 8,	0
203	Feasibility and results of an intensive cardiac rehabilitation program. Insights from the MxM (M <sub>é</sub> por Menos) randomized trial. <b>2021</b> , 74, 518-525	
202	Distribution, management and outcomes of AMI according to principal diagnosis priority during inpatient admission. <b>2021</b> , 75, e14554	
201	Triglyceride glucose index combined with plaque characteristics as a novel biomarker for cardiovascular outcomes after percutaneous coronary intervention in ST-elevated myocardial infarction patients: an intravascular optical coherence tomography study. <b>2021</b> , 20, 131	5
200	Factibilidad y resultados de un programa de rehabilitaci3n cardiaca intensiva. Perspectiva del estudio aleatorizado MxM (M <sub>é</sub> por Menos). <b>2021</b> , 74, 518-525	0
199	Cardiorespiratory fitness measured with cardiopulmonary exercise testing and mortality in patients with cardiovascular disease: A systematic review and meta-analysis. <b>2021</b> ,	4
198	Predictors for Long-Term Prognosis after Acute Coronary Syndrome. <b>2021</b> , 14, 31-46	
197	De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. <b>2021</b> , 2021,	78
196	Usefulness of FT3 to FT4 Ratio to Predict Mortality in Euthyroid Patients With Prior Cardiovascular Events Undergoing PCI: Five-Year Findings From a Large Single-Center Cohort Study. <b>2021</b> , 12, 700349	1
195	Aortic Valve Sclerosis in High-Risk Coronary Artery Disease Patients. <b>2021</b> , 8, 711899	1
194	Non-culprit MACE-rate in LRP: The influence of optimal medical therapy using DAPT and statins. <b>2021</b> ,	0
193	Cardiac Rehabilitation: Under-Utilized Globally. <b>2021</b> , 23, 118	7
192	Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies. <b>2021</b> , 78, 809-816	10
191	Colchicine in the Management of Acute and Chronic Coronary Artery Disease. <b>2021</b> , 23, 120	0
190	High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?. <b>2021</b> , 9,	2

189	CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG CARDIAC REHABILITATION AND NON CARDIAC REHABILITATION GROUPS-A PROSPECTIVE OBSERVATIONAL STUDY. <b>2021</b> , 25-27	
188	Sex-based outcomes in contemporary antiplatelet therapy trials. <b>2021</b> , 8,	1
187	Resonancia magnética cardíaca de estrés para predecir mortalidad y toma de decisiones: registro de 2.496 pacientes mayores con síndrome coronario crónico. <b>2021</b> , 75, 223-223	4
186	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <b>2021</b> , 37, 1837-1845	1
185	Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. <b>2021</b> , 14, 831-840	1
184	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <b>2021</b> , 1	3
183	Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. <b>2021</b> , 1	1
182	Hospitalization for Myocardial Infarction with Ticagrelor or Clopidogrel in Patients with Acute Coronary Syndrome: An On-Treatment Comparative Effectiveness Analysis. <b>2021</b> , 10, 515-529	0
181	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <b>2021</b> , 44, 1333-1343	1
180	Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents. <b>2021</b> , 10,	0
179	Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction. <b>2021</b> , 10, e019270	2
178	Nurse-based secondary preventive follow-up by telephone reduced recurrence of cardiovascular events: a randomised controlled trial. <b>2021</b> , 11, 15628	0
177	Stress cardiac magnetic resonance for mortality prediction and decision-making: registry of 2496 elderly patients with chronic coronary syndrome. <b>2021</b> , 75, 223-223	1
176	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). <b>2021</b> , 19, 451-468	2
175	Inflammation during the life cycle of the atherosclerotic plaque. <b>2021</b> , 117, 2525-2536	16
174	Trends in the Use of Cardiac Rehabilitation in Japan Between 2010 and 2017 - An Epidemiological Survey. <b>2021</b> , 3, 569-577	2
173	The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy. <b>2021</b> , 21, 466	0
172	Predictors of Recurrent Ischemic Events in Patients With ST-Segment Elevation Myocardial Infarction. <b>2021</b> , 159, 44-51	3

171	Preylcysteine oxidase 1, an emerging player in atherosclerosis. <b>2021</b> , 4, 1109	1
170	Safety and Feasibility of Same Day Discharge Strategy for Primary Percutaneous Coronary Intervention. <b>2021</b> , 16, 46	1
169	[Detection of peripheral artery disease in patients with ischemic heart disease. A quick guide for medical practitioners]. <b>2021</b> , 60, 125-132	
168	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <b>2020</b> , 42, e49-e58	4
167	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <b>2020</b> , 120, 412-422	12
166	Association between $\beta$ blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. <b>2021</b> , 10, 372-379	4
165	A Practical Risk Score to Predict 24-Month Post-Discharge Mortality Risk in Patients With Non-ST-Segment Elevation Myocardial Infarction. <b>2020</b> , 84, 1974-1980	1
164	MicroRNA-668-3p Protects Against Oxygen-Glucose Deprivation in a Rat H9c2 Cardiomyocyte Model of Ischemia-Reperfusion Injury by Targeting the Stromal Cell-Derived Factor-1 (SDF-1)/CXCR4 Signaling Pathway. <b>2020</b> , 26, e919601	2
163	Emerging strategies to prevent heart failure after myocardial infarction. 4, 37	1
162	Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study. <b>2017</b> , 12, e0180010	9
161	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <b>2017</b> , 12, e0186961	15
160	Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era. <b>2017</b> , 12, 89-91	15
159	. <b>2019</b> , 59, 68-78	2
158	[Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don)]. <b>2019</b> , 59, 97-100	2
157	Mobile Technology Utilization Among Patients From Diverse Cultural and Linguistic Backgrounds Attending Cardiac Rehabilitation in Australia: Descriptive, Case-Matched Comparative Study. <b>2018</b> , 2, e13	2
156	Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT Post-MI study. <b>2021</b> , 22, 478-485	2
155	Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events?. <b>2015</b> , 6, 12-19	6
154	Influence of Local Myocardial Infarction on Endothelial Function, Neointimal Progression, and Inflammation in Target and Non-Target Vascular Territories in a Porcine Model of Acute Myocardial Infarction. <b>2019</b> , 34, e145	2

153	Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 21,	2
152	Co-Design Process of a Virtual Community of Practice for the Empowerment of People with Ischemic Heart Disease. <b>2020</b> , 20, 9	3
151	Triglyceride-Glucose Index as a Surrogate Marker of Insulin Resistance for Predicting Cardiovascular Outcomes in Nondiabetic Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <b>2021</b> , 28, 1175-1194	9
150	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <b>2020</b> , 27, 661-676	4
149	Effect of personal activity intelligence (PAI) monitoring in the maintenance phase of cardiac rehabilitation: a mixed methods evaluation. <b>2021</b> , 13, 124	1
148	Endogenous fibrinolysis inhibitors in acute coronary syndrome. <b>2021</b> , 10, 100058	
147	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.. <b>2022</b> , 4, 206-213	1
146	Factores determinantes del riesgo isquémico del paciente tras un infarto agudo de miocardio. <b>2017</b> , 17, 9-15	
145	Comparison of myocardial infarction mortality rates in the regions of the Russian Federation in 2006 and 2015. <b>2017</b> , 20, 11	3
144	The influence of smoking on the clinical effects of a one-year program of physical rehabilitation of patients of working age who underwent acute myocardial infarction. <b>2017</b> , 8, 20-29	0
143	Drug Adherence with Cardiovascular Medicines: Statins and Aspirin. <b>2018</b> , 199-217	
142	Innate Immune Mechanisms in Myocardial Infarction - An Update. <b>2018</b> , 26, 9-20	1
141	Do You Know How Young Your Heart Is?. <b>2018</b> , 24, 66-71	
140	DYNAMICS OF THE PREVALENCE BY VISIT OF ARTERIAL HYPERTENSION, CORONARY HEART DISEASE AND COMPLICATIONS DURING 6 YEARS IN RURAL AREAS INHABITANTS. <b>2018</b> , 17, 65-70	
139	Influence of tobacco smoking on clinical efficacy of a 1-year rehabilitation programme for myocardial infarction patients of economically active age. <b>2018</b> , 17, 26-33	1
138	Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations. <b>2019</b> , 20-29	
137	[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board]. <b>2019</b> , 59, 58-64	1
136	Role of miRNAs induced by oxidized low-density lipoproteins in coronary artery disease: the REGICOR Study.	

- 135 Prescription drug coverage in high cardiovascular risk patients as an important part of the national goals achievement. **2019**, 2019, 20-27 2
- 134 [Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]. **2019**, 91, 129-134
- 133 Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry. **2020**, 11, 311-318
- 132 Long term antithrombotic therapy after myocardial infarction: why, to whom and which one?. **2020**, 66, 160-168
- 131 Secondary prevention after acute coronary syndrome. **2020**, 66, 236-241
- 130 Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. **2020**, 13, 695-706 2
- 129 Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. **2020**, 35, 1045-1058 4
- 128 Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. **2020**, 42, e65-e71 2
- 127 Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. **2020**, 42, e59-e64 2
- 126 Temporal changes in the secondary prevention of coronary artery disease in patients following myocardial revascularization. **2020**, 16, 422-428
- 125 The State of Medical Assistance for Acute Coronary Syndrome in the Inhabitants of the Transcarpathian Mountain Regions. **2020**, 5, 187-191
- 124 [Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]. **2020**, 60, 131-141
- 123 Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. **2021**, 21, 241 8
- 122 Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. **2021**, 0
- 121 Cost-utility analysis of evolocumab in patients with ASCVD in Italy. **2021**, 8, 155-167
- 120 Modern Approaches to Optimal Antithrombotic Therapy for Stable Ischemic Heart Disease. **2020**, 10, 348-356
- 119 Prediction of recurrent myocardial infarction in working-age patients. **2020**, 25, 3909
- 118 PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders. **2020**, 25, 4010 2



117	[Experience of the use of the PCSK9 inhibitor Alirocumab in patients with extremely high cardiovascular risk]. <b>2020</b> , 60, 71-77		0
116	Treatable Traits in COPD - A Proposed Approach. <b>2021</b> , 16, 3167-3182		1
115	Zwolle Risk Score for Safety Assessment of Same-day Discharge after Primary Percutaneous Coronary Intervention.. <b>2021</b> , 33, 332-338		0
114	Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction.. <b>2021</b> , 8, 783344		1
113	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <b>2021</b> ,		0
112	Temporal Trends and Outcome of Patients with Acute Coronary Syndrome and Prior Myocardial Infarction. <b>2021</b> , 10,		0
111	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. <b>2021</b> , 10, e023129		
110	Innate Lymphoid Cells and Myocardial Infarction. <b>2021</b> , 12, 758272		0
109	Prognostic Significance of Triglyceride-Glucose Index for Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.. <b>2021</b> , 8, 774781		1
108	Intervention and in-hospital pharmacotherapies in octogenarian with acute coronary syndrome: a 10-year retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry.. <b>2022</b> , 22, 23		
107	Impact of age, gender and heart failure on mortality trends after acute myocardial infarction in Italy.. <b>2021</b> ,		2
106	Modifiable and Non-modifiable Risk Factors in Myocardial Infarction in the Iranian Population. <b>2020</b> , 1, 21-28		
105	Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction. <b>2022</b> , 11, 18-28		
104	The Effects of Comprehensive Home-Based Cardiac Rehabilitation versus Usual Care in Patients with Ischemic Heart Disease in Iran: Study Protocol for a Multicenter Randomized Controlled Trial.. <b>2022</b> , 13, 4		
103	Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	3
102	Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention.. <b>2022</b> , 9,		1
101	Dual-Antiplatelet Therapy in Patients With Prior Myocardial Infarction: The Twilight of Prolonged DAPT Duration?. <b>2022</b> , 15, 294-294		
100	What is the Optimal Low-Density Lipoprotein Cholesterol?. <b>2022</b> , 106, 285-298		

99	Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.. <b>2021</b> , 246, 44-44	0
98	The effect of statin adherence on patients with type 2 diabetes after percutaneous coronary intervention for acute coronary syndrome.. <b>2022</b> , 1	
97	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.. <b>2021</b> , 19, 102	0
96	The influence of biological age and sex on long-term outcome after percutaneous coronary intervention for ST-elevation myocardial infarction. <b>2021</b> , 11, 659-678	
95	Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome: an observational, retrospective cohort study.. <b>2022</b> ,	0
94	Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis.. <b>2022</b> , 1	
93	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction.. <b>2022</b> , 9, 797297	0
92	Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review.. <b>2022</b> ,	0
91	Trends in Ambulatory Analgesic Usage after Myocardial Infarction: A Nationwide Cross-Sectional Study of Real-World Data.. <b>2022</b> , 10,	1
90	Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study.. <b>2022</b> ,	0
89	[Long-term course of heart disease: How can psychosocial care be improved?]. <b>2022</b> , 65, 481	1
88	Health-Related Quality of Life and Its Influencing Factors in Patients with Coronary Heart Disease in China.. <b>2022</b> , 16, 781-795	1
87	The effectiveness of cardiac telerehabilitation in comparison to centre-based cardiac rehabilitation programmes: A literature review.. <b>2022</b> , 1357633X221085865	4
86	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.. <b>2022</b> ,	16
85	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization.. <b>2022</b> , 11,	
84	Kardiovaskuläre Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung. <b>2021</b> , 21, 35-38	
83	Widening or narrowing income inequalities in myocardial infarction? Time trends in life years free of myocardial infarction and after incidence.. <b>2021</b> , 19, 47	1
82	When More Means Less: The Prognosis of Recurrent Acute Myocardial Infarctions.. <b>2021</b> , 10,	

- 81 Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. **2021**, 21, 583 2
- 80 Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in Norway.. **2021**,
- 79 Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity on Peak Oxygen Uptake and Myocardial Fibrosis in Patients With Myocardial Infarction: Protocol for a Randomized Controlled Trial.. **2022**, 9, 860071 1
- 78 Immune and Inflammatory Networks in Myocardial Infarction: Current Research and Its Potential Implications for the Clinic.. **2022**, 23, 1
- 77 Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.. **2022**, 0
- 76 An Ensemble Learning Method for Constructing Prediction Model of Cardiovascular Diseases Recurrence. **2022**, 208-220
- 75 [The importance of cardiorehabilitation in the era of modern treatment of cardio-vascular diseases].. **2022**, 62, 3-11
- 74 Automated Coronary Optical Coherence Tomography Feature Extraction with Application to Three-Dimensional Reconstruction. **2022**, 8, 1307-1349 0
- 73 Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. **2022**, 9, 17-26
- 72 Prognostic Value of Combining Apelin-12 and Estimated Glomerular Filtration Rate in Patients with ST-Segment Elevation Myocardial Infarction. **2022**, 2022, 1-9
- 71 Impact of multicomponent integrated care on mortality and hospitalization after acute coronary syndrome: a systematic review and meta-analysis. 0
- 70 Escenario II. Optimizaci3n del control lip3dico despu3s de un s3ndrome coronario agudo: la transici3n entre el servicio de cardiolog3a y atenci3n primaria. **2022**, 22, 7-10
- 69 Predicting Return to Work Following Myocardial Infarction: A Prospective Longitudinal Cohort Study. **2022**, 19, 8032 0
- 68 Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials. **2022**, 12, e062702 0
- 67 Role of Inflammation in Cardiac Remodeling After Acute Myocardial Infarction. 13, 0
- 66 Exploring patients'and relatives'needs following acute myocardial infarction: a qualitative study.
- 65 Predictors of recurrent acute myocardial infarction despite initially successful percutaneous coronary intervention: back to the basic. **2022**, 37, 740-741
- 64 Cardiac rehabilitation and secondary prevention after acute myocardial infarction: a modern view on the problem. **2022**, 27, 571-587

63 Long-term vascular events after subarachnoid hemorrhage.

62 Impact of elevated systolic arterial pulmonary pressure on the total mortality rate after acute myocardial infarction in the elderly. **2022**, 12, ○

61 Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. **2022**, ○

60 Trajectories of Blood Pressure in Patients with Established Coronary Artery Disease over 20 years. **2022**, 2022, 1-7

59 Prognostic implications for patients after myocardial infarction: an integrative literature review and in-depth interviews with patients and experts. **2022**, 22,

58 Global research trends in atherosclerosis: A bibliometric and visualized study. 9, ○

57 Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI. ○

56 Duration of Dual Antiplatelet Therapy in East Asians: Finding the Balance Between Effectiveness and Safety. **2022**, 80, 200-202

55 Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK. **2022**, 56, 337-342

54 Prevalence and determinants of return to work after various coronary events: meta-analysis of prospective studies. **2022**, 12, ○

53 Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. **2022**, 184, 106439 2

52 Women-Focused Cardiovascular Rehabilitation: An International Council of Cardiovascular Prevention and Rehabilitation Clinical Practice Guideline. **2022**, ○

51 Comparison of Clinical Outcomes after Non-ST-Segment and ST-Segment Elevation Myocardial Infarction in Diabetic and Nondiabetic Populations. **2022**, 11, 5079 ○

50 Qualitative study measuring the usability of the International Cardiac Rehabilitation Registry. **2022**, 12, e064255 1

49 The Association Between a Second Course of Cardiac Rehabilitation and Cardiovascular Outcomes Following Repeat Percutaneous Coronary Intervention Events. Publish Ahead of Print, ○

48 Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. **2022**, 17, e0268709 ○

47 Controlled pilot test of a translated cardiac rehabilitation education curriculum in percutaneous coronary intervention patients in a middle-income country delivered using WeChat: acceptability, engagement, satisfaction and preliminary outcomes. **2022**, 37, 314-332 ○

46 Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. ○

45	Macrophage Rmp Ameliorates Myocardial Infarction by Modulating Macrophage Polarization in Mice. <b>2022</b> , 2022, 1-12	0
44	Nurses' perspectives on the barriers to and facilitators of the implementation of secondary prevention for people with coronary heart disease: a qualitative descriptive study. <b>2022</b> , 12, e063029	0
43	Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes.	3
42	Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis. <b>2022</b> , 30, 3118-3132	0
41	Predictive worth of estimated glucose disposal rate: evaluation in patients with non-ST-segment elevation acute coronary syndrome and non-diabetic patients after percutaneous coronary intervention. <b>2022</b> , 14,	0
40	Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry.	0
39	The Effects of Angiotensin Receptor-Nepriylsin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.	0
38	Percutaneous coronary intervention in patients aged 80 years old and above: a systematic review and meta-analysis. <b>2022</b> , 8, 123-131	0
37	Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial. 1-9	0
36	Relationship between a novel noninsulin-based metabolic score for insulin resistance (METS-IR) and coronary artery calcification. <b>2022</b> , 22,	1
35	Technology-based Comprehensive Cardiac Rehabilitation Therapy (TaCT) for women with cardiovascular disease in a middle-income setting: A randomized controlled trial protocol.	0
34	Preoperative lymphocyte to C-reactive protein ratio: A new prognostic indicator of post-primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. <b>2023</b> , 114, 109594	0
33	Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study.	0
32	Sex-specific features of optical coherence tomography detected plaque vulnerability related to clinical outcomes: insights from the CLIMA study.	0
31	Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts. <b>2022</b> ,	0
30	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,	0
29	Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (Üena auf Ziel)	0
28	Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <b>2022</b> , 11, 232-242	3

- 27 Effect of Dendrobine on Cardiac Dysfunction in Rats with Myocardial Infarction by Regulating Autophagy. **2023**, 13, 66-72 ○
- 26 Endothelial dysfunction predicts bleeding and cardiovascular death in acute coronary syndrome. **2023**, 376, 11-17 ○
- 25 Long-term follow-up of survivors of a first acute coronary syndrome: Results from the French MONICA registries from 2009 to 2017. **2023**, 378, 138-143 ○
- 24 Risk of early recurrence and mortality in high-risk myocardial infarction patients: A population-based linked data study. **2023**, 17, 200185 ○
- 23 Fall Prevention in Community-Dwelling Older Adults. **2022**, 91-101 ○
- 22 The Clock Is Ticking: The Imminent Need to Re-evaluate the Standard of Care in the 90-Day High-Risk Post-Acute Myocardial Infarction Period. 2-6 ○
- 21 NDRG1: A New Regulator of Vascular Inflammation and Atherothrombosis. **2023**, 132, 320-322 ○
- 20 Long-term risk, clinical management, and healthcare resource utilization of stable patients with coronary artery disease and post-myocardial infarction in Greece - TIGREECE study. **2023**, ○
- 19 Circulating Total Bilirubin and Long-Term Prognosis in Patients With Previous Myocardial Infarction. **2023**, 3, 242-251 ○
- 18 Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. ○
- 17 Can carotid plaque assessment perform the role of a risk predictor for secondary prevention?. **2023**, 376, 154-155 ○
- 16 High triglyceride-glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents. 14, ○
- 15 Effectiveness of a structured pharmacist-delivered intervention for patients post-acute coronary syndromes on all-cause hospitalizations and cardiac-related hospital readmissions: a prospective quasi-experimental study. ○
- 14 Thymosin  $\alpha$  and MRTF-A mitigate vessel regression despite cardiovascular risk factors. **2023**, 117, 109786 ○
- 13 Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis. **2023**, ○
- 12 Incidence and predictors of cardiovascular outcomes after acute coronary syndrome in a population-based cohort study. **2023**, 13, ○
- 11 Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. ○
- 10 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○

- 9 Thrombozytenaggregationshemmung nach Koronarintervention (PCI). **2023**, 19, 41-56 ○
- 8 Integrated solution for patients of a very high cardiovascular risk. Final results. **2023**, 28, 5358 ○
- 7 Towards Fairness and Interpretability: Clinical Decision Support for Acute Coronary Syndrome. **2022**, ○
- 6 Cognitive testing following transient ischaemic attack: A systematic review of clinical assessment tools. **2023**, 10, ○
- 5 Predictors of Readmission after the First Acute Coronary Syndrome and the Risk of Recurrent Cardiovascular Events Seven Years of Patient Follow-Up. **2023**, 13, 950 ○
- 4 Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction. ○
- 3 Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes. **2023**, 102, e33026 ○
- 2 Prognostic impact of fractional flow reserve measurements in patients with acute coronary syndromes: a subanalysis of the FLORIDA study. ○
- 1 Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid. **2023**, 25, B55-B59 ○